Eloralintide And Tirzepatide
AMPLIFY-1
Eli Lilly · Phase 3 · Not yet recruiting · Enrollment 2115
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| EloraTZP Dose 1 | n/r | n/r | n/r | n/r |
| EloraTZP Dose 2 | n/r | n/r | n/r | n/r |
| EloraTZP Dose 3 | n/r | n/r | n/r | n/r |
| EloraTZP Dose 4 | n/r | n/r | n/r | n/r |
| EloraTZP Dose 5 | n/r | n/r | n/r | n/r |
| Tirzepatide | n/r | n/r | n/r | n/r |
| Eloralintide | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- EloraTZP Dose 1: endpoint not reported
- EloraTZP Dose 2: endpoint not reported
- EloraTZP Dose 3: endpoint not reported
- EloraTZP Dose 4: endpoint not reported
- EloraTZP Dose 5: endpoint not reported
- Tirzepatide: endpoint not reported
- Eloralintide: endpoint not reported
- Placebo: endpoint not reported